Analyst Reco. G1 Therapeutics, Inc.

Equities

GTHX

US3621LQ1099

Real-time Estimate Cboe BZX Other stock markets 02:02:46 2024-06-04 pm EDT			5-day change	1st Jan Change
3.145 ^USD	-2.63%		-7.50%	+3.11%

May. 28	G1 Therapeutics, Inc. Announces the Presentation of Mature Phase 2 Clinical Trial Results	CI
May. 23	G1 Therapeutics Announces Upcoming Presentation at the 2024 American Society of Clinical Oncology Meeting	CI

Analyst Reco.

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Wedbush Lifts G1 Therapeutics' PT to $5 From $4, Adjusts Financing, Revenue Expectations; Keeps Outperform Rating	Feb. 28	MT
Needham Adjusts G1 Therapeutics Price Target to $12 From $14, Maintains Buy Rating	Feb. 13	MT
Wedbush Adjusts G1 Therapeutics' PT to $4 From $5, Keeps Outperform Rating	Feb. 13	MT
JPMorgan Downgrades G1 Therapeutics to Underweight From Neutral	23-10-06	MT
Raymond James Adjusts Price Target on G1 Therapeutics to $8 From $24, Maintains Outperform Rating	23-05-04	MT
Needham Cuts Price Target on G1 Therapeutics to $18 From $31, Maintains Buy Rating	23-02-14	MT
HC Wainwright Lowers Price Target on G1 Therapeutics to $11 From $34, Maintains Buy Rating	23-02-14	MT
EF Hutton Adjusts Price Target on G1 Therapeutics to $19 From $35, Maintains Buy Rating	23-02-13	MT
JPMorgan Upgrades G1 Therapeutics to Neutral From Underweight, Adjusts Price Target to $10 From $7	23-01-30	MT
EF Hutton Initiates G1 Therapeutics at Buy With $35 Price Target	23-01-05	MT
G1 Therapeutics Says Phase 2 Trial Shows Objective Response Rate of 40% in Patients With Bladder Cancer	23-01-04	MT
Needham Adjusts Price Target on G1 Therapeutics to $31 From $32, Maintains Buy Rating	23-01-03	MT
HC Wainwright Adjusts G1 Therapeutics Price Target to $57 From $67, Maintains Buy Rating	22-11-02	MT
Wedbush Lifts Price Target on G1 Therapeutics to $25 From $20, Citing Trilaciclib Potential, Keeps Outperform Rating	22-09-16	MT
Needham Adjusts Price Target on G1 Therapeutics to $32 From $42, Reiterates Buy Rating	22-08-04	MT
Needham Adjusts G1 Therapeutics' Price Target to $42 from $44, Keeps Buy Rating	22-05-05	MT
Wedbush Cuts G1 Therapeutics' Price Target to $20 From $24, Citing Cost of Capital; Outperform Rating Kept	22-05-05	MT
Raymond James Adjusts Price Target on G1 Therapeutics to $24 from $41, Keeps Outperform Rating	21-11-04	MT
HC Wainwright Adjusts G1 Therapeutics' Price Target to $71 from $78, Keeps Buy Rating	21-11-04	MT
JP Morgan Downgrades G1 Therapeutics to Underweight Rating From Neutral, Adjusts Price Target to $19 From $20	21-11-04	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Analyst Reco. G1 Therapeutics, Inc.

Equities

GTHX

US3621LQ1099

Analyst Reco.

Filters